Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 9Ovarian Neoplasms 5Carcinoma, Non-Small-Cell Lung 3Pancreatic Neoplasms 2Multiple Myeloma 2Stomach Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms by Site 1Neoplasm Metastasis 1Lung Neoplasms 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Digestive System Neoplasms 1Colorectal Neoplasms 1Bites and Stings 1Adenocarcinoma 1

Interventions

Gemcitabine 4130-nm albumin-bound paclitaxel 4pembrolizumab 3napabucasin 3Paclitaxel 3Irinotecan 3selpercatinib 2pralsetinib 2patritumab 2Standard of Care 2Pemetrexed 2Nivolumab 2Fluorouracil 2Cyclophosphamide 2Cisplatin 2Carboplatin 2Ascorbic Acid 2Albumin-Bound Paclitaxel 2valrubicin 1sotorasib 1ribociclib 1relatlimab 1pamiparib 1osimertinib 1ipatasertib 1durvalumab 1dostarlimab 1cobimetinib 1atezolizumab 1alectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasms by Site × dostarlimab × Clear all
NCT05980416 2025-11-14

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Elevation Oncology

Phase 1 Terminated
88 enrolled 18 charts
Gastrointestinal

Adenocarcinoma, Digestive System Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Neoplasms by Site, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡